1 / 23

TEKNA Oslo Plaza 16.10.09 PhD utdanningen Umodne arbeids- & kunnskapsmarked Bioteknologi

TEKNA Oslo Plaza 16.10.09 PhD utdanningen Umodne arbeids- & kunnskapsmarked Bioteknologi Berit Johansen, professor og gründer Avexxin AS/NTNU. Berit Johansen, IBI mars 2006. OECDs definisjon av Bioteknologi:

teddy
Download Presentation

TEKNA Oslo Plaza 16.10.09 PhD utdanningen Umodne arbeids- & kunnskapsmarked Bioteknologi

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TEKNA Oslo Plaza 16.10.09 PhD utdanningen Umodne arbeids- & kunnskapsmarked Bioteknologi Berit Johansen, professor og gründer Avexxin AS/NTNU Berit Johansen, IBI mars 2006

  2. OECDs definisjon av Bioteknologi: "Anvendelse av naturvitenskap og teknologi på levende organismer og på deler, produkter og modeller av disse, slik at levende eller ikke-levende materiale endres for å frembringe kunnskap, varer og tjenester."

  3. Bioteknologisk industri–en ung industri? Verdens første biotekfirma: Genentech (1976) San Fransisco, US, Swanson og Boyer. Biogen Inc (1978) Geneve, SCH, W. Gilbert (Nobelprisen i 1980)

  4. Det Globale Biotek Racet –økonomisk betydelig? “Our biotechnology industry is the strongest in the world – and we need to keep it that way” President George W. Bush, Bio 2003 in Washington DC ”Public research across EU to the value of € 70 billion is unexploited” Former EU Director of Research Bruno Hansen, MVA BioConference 2002 US biotech turnover is expected to increase to an almost 20% GDP contribution in year 2010

  5. Biotechnology Outlook European biotechnology industry younger and lags the US on several parameters USA (2001): Europe (2001): 1879 191,000 1457 No. biotech companies Employees Product Pipeline* VC investments Revenues R&D Expenses Net Loss Market Cap 87,200 300 319 22 bnUSD 5 bnUSD 1,2 bnUSD 12,1 bnUSD 13,9 bnUSD 225 bnUSD 45 bnUSD 6,6 bnUSD 6,1 bnUSD 1,3 bnUSD * No. of drug candidates in clinical development

  6. Germany had the most companies…

  7. Lord Sainsbury, UK minister of Science and Innovation, at BioTech Forum Science conf. oct.o4, Copenhagen: • doubling in government spending on science • from 1998-2005: £ 3 bn (2005) • at present largest biotech country in Europe • UK Biotech companies: 485 (2004) • Biotech employment: 26.000 • UK Biotech products in clinical testing: 40% of • EU drug candidates • UK Biotech secure more than 40% of European VC

  8. Major Bio-clusters world wide

  9. Bostonwww.boston.com/www.massbio.org • 280 biotechnology companies • Biotech and drug companies employ more than 30,000 people

  10. Cambridge and east of Englandwww.erbi.co.uk • 185 biotech companies • 20% of the world's Nobel Prize winners in medicine and chemistry

  11. Bay Area, Northern Californiawww.bayareafirst.org • More than 600 bioscience companies and 820 life science companies • 24% of the $300 billion U.S. biotech market cap isin the Bay Area; 68% is in the state of California (2004 figures) • 30% of total U.S. venture capital funding went to companies located in the Bay Area (2004 figure) • Venture capital firms invested $797 million in local biopharmaceutical companies (2003 figure) • 5 world-renowned research universities

  12. San Diegowww.milkeninstitute.com* • 21,000 employed in life science industry • 178 Life Science companies • UCSD 10 Nobel laureates • NIH awarded research funds 2003: 316 M USD • 12 Biotech Research Institutes * Data from analysis by Milken institute

  13. Stockholm-Uppsalawww.uppsalabio.com/www.stockholmbioregion.comStockholm-Uppsalawww.uppsalabio.com/www.stockholmbioregion.com • 230 companies with 20,000 employees • 5 universities • 3,750 scientists and 6,160 PhD students • 8 Nobel Laureates within Medicine and Chemistry

  14. Medicon Valleywww.mediconvalley.com/www.mva.org • Population 3 million • 14 universities - all part of the Öresund University • 150,000 university students • 5,000 life science researchers • 26 hospitals, of which 11 are university hospitals • 41,000 people employed in life science • More than 500 companies within the biotech, medtech and human life science fields - more than 200 companies work within R&D • A strong infrastructure within the health care sector • Excellence in some of the most commercially attractive disease areas • Copenhagen Airport - Scandinavia's main airport - has approx. 20 million national and international passengers annually

  15. University ranking 2005From top 100 World University ranking. From: Institute of Higher Education, Shanghai Jiao Tong University, • Region ranked by top University • Boston: Harvard:1, MIT:5, Boston:80, Tuffts:100 • Cambridge UK :2 • Bay Area: Stanford:3, Berkley:4, UCSF:18, Davis: 41 • New York: Columbia:7, NY U:29, Rockefeller:30, • Oxford:10 • San Diego: UCSD:13 • London: Imperial Coll:23, Univ Coll:26, Kings Coll:80 • Res. Triangle: Duke: 32, Chapel Hill:55 • Stockholm/Uppsala: Karolinska: 45, Uppsala:60, Stockholm:93 • Paris: U.Paris-06:46, U.Paris-11:61, ENSP:93 • Medicon Valley: Copenhagen:57, Lund:99 • BioValley; Basel:87, Freiburg:90, Strasbourg:92

  16. Norwegian Biotech Industry Norwegian biotech industry sorted according to subsector. A total of 110 companies employ close to 5000 people and generate total revenue of NOK 12 billion (2004).

  17. Norsk Biotek-industri fordelt etter universitets-tilhørighet (2005)

  18. PhD–utdanning i Bioteknologi Hittil ved norske universiteter: • Teknologi- prosessbasert, f.eks fermentering • Molekylærbiologi-baserte

  19. PhD–utdanning i Bioteknologi Utfordringer: • Behovet for forsker-arbeidskraft i bioteknologiindustrien er skiftet fra det teknologibaserte til det vitenskapsbaserte • Dagens “big pharma” har ikke lengre egne legemiddelkandidater, og er avhengige av biotekfirma for å fylle sine “pipelines” • En nisje skapes derved for vitenskapsbaserte bioteknologifirma

  20. PhD–utdanning i Bioteknologi Morgendagens utdanning: • Vitenskapsbasert, høykvalitets forskning etter internasjonale suksesskriterier • Tverrfaglig (celle/molekylærbiologi, immunologi, biokjemi, FUGE, statistisk/datavitenskapelig kunnskapsoppdaging) • Bevissthet rundt patentering/kommersialiserings-mekanismer

  21. Takk for oppmerksomheten!

More Related